Introduction {#S1}
============

Age-related macular degeneration (AMD) is a progressive and degenerative eye disease that is a leading cause of vision loss among the elderly population ([@B24]). It is estimated that the number of individuals affected by AMD in 2020 will reach 196 million and that the number will grow to 288 million in 2040 ([@B74]). Because of its socioeconomic impact together with the growing incidence and severity of the disease, AMD has become a major challenge in ophthalmology in recent years. However, the exact pathophysiology of AMD has not been fully elucidated, which hampers the possibility of developing efficient therapeutic options.

Two major clinical subtypes of AMD have been established: dry (atrophic) and wet (exudative, neovascular) AMD. Dry AMD is characterized by drusen accumulation and progressive geographic atrophy of the retinal pigment epithelium (RPE) and retina, whereas wet AMD is described by the growth of largely malformed leaky choroidal vessels into the retina ([@B18]). The prevalence of dry AMD is higher than that of wet AMD, comprising 80--85% of all cases; however, wet AMD accounts for 90% of all clinical cases with loss of sight, and the rapid visual acuity loss in wet AMD may occur within several months ([@B6]). The pathogenesis of AMD remains unclear, although both genetic and environmental factors play a role. The complex etiology of this disease has been linked to various cellular, biochemical, and molecular events, from which inflammation emerges as crucial in AMD pathogenesis and progression ([@B55]; [@B33]).

Inflammation is a complex response induced by foreign material and/or tissue damage and is highly advantageous in the short term because it eliminates dangerous stimuli and initiates tissue recovery. However, long-term inflammation is detrimental; prolonged low-level inflammation has been linked with chronic conditions, such as cancer, diabetes, neurodegenerative diseases and others ([@B25]).

The first report of inflammatory processes involved in AMD histopathology was published in [@B23]. Since then, several research groups have established that aggregates of choroidal leukocyte infiltrates are associated with disciform macular lesions ([@B19]). In further studies, [@B57] demonstrated the involvement of inflammatory cells (including macrophages, lymphocytes, and mast cells) in RPE atrophy and Bruch's membrane breakdown. Macrophages release a range of mediators, mainly pro-inflammatory and pro-angiogenic, and their recruitment has been proposed in both wet and dry AMD forms ([@B2]). Microglia, the immunocompetent resident macrophages, are equally distributed in the plexiform layers of the retina and possess a wide array of immune surface proteins (receptors for complement components, cytokines, chemokines) to sense their environment for on/off inflammatory signals ([@B32]; [@B61]). Microglial cells when activated in degenerative process may release different inflammatory mediators including cytokines, chemokines, reactive oxygen species (ROS), and nitric oxide (NO), all of them contributing to the maintenance of a chronic neuroinflammatory environment that initially plays essential role in protecting retinal tissue during the early steps of its degeneration ([@B13]). However, continuous presence of proinflammatory stimuli induces locally the cellular damage which together with retinal drusen can subsequently attract other reactive systemic immune cells to the retina ([@B5]). In case of prolonged insult to the retina, the overreactive neurotoxic microglia release large amounts of pro-inflammatory and cytotoxic factors such as TNF-α and IL-1β, creating a proinflammatory environment favorable for further recruitment of retinal microglia and exogenous infiltrating monocytes ([@B65]; [@B79]). Recent findings of [@B52] confirm the interplay between local and systemic response in AMD: the group has shown that photo-oxidative damage induced an early pro-inflammatory and chemokine-driven response which triggered microglia/macrophage recruitment to the photoreceptor lesion. Although the clinical presentation of AMD is mainly limited to the retina, this notable involvement of inflammatory cells points to a possible systemic inflammatory response occurring with AMD. Since systemic activation of the complement cascade has also been observed in AMD patients ([@B47]; [@B48]; [@B35]), it is possible that inflammatory factors in the circulation could also contribute to the pathogenesis of AMD via exchange between the choroid and the retina ([@B10]). Several studies have shown altered inflammatory cytokine profiles in AMD patients ([@B64]), highlighting their potential role in the pathogenesis of this disease.

Another evidence of circulating factors involvement in AMD pathogenesis comes from studies on drusen constituents -- many of them are serum proteins ([@B28]). The drusen are also composed of inflammatory factors and complement cascade components ([@B12]). The accumulation of intracellular lipofuscin in the RPE triggers intracellular oxidative stress and subsequent inflammation by activation of innate immune cells of myeloid origin such as macrophages and microglia.

On the other hand in wet form of disease the injured RPE produces VEGF, interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP), which attract monocytes from the choriocapillaris along the outer surface of Bruch's membrane ([@B45]) resulting in the breakdown of the blood-retinal barrier and development of new vessels. The macrophages then express TNF-α and interleukin-1 (IL-1), which up-regulate complement factor-B ([@B72]), activate the complement alternative pathway in the subretinal space, and stimulate RPE cells to produce even more VEGF ([@B20]). Parallel to VEGF, the pro-inflammatory cytokine, interleukin 6 (IL-6) has also been found to play an important role in the development of CNV. IL-6 was found to be increased in the serum and eye aqueous humor of patients with neovascular AMD ([@B27]). [@B60] reported a significant decrease in IL-6 levels due to regression of CNV that occurred in response to anti-VEGF treatment.

As AMD combines neovascularization with retinal inflammation, the suppression of inflammation and vessel growth prevention appears as the two emerging strategies for its treatment. Nowadays, the anti-inflammatory treatment is being widely investigated with a number of approaches, including complement inhibition ([@B15]). However, the results are still far from satisfactory.

A major role in governing various pathological processes that contribute to AMD pathogenesis, including inflammation, is attributed to microRNAs (miRNAs, miRs) ([@B34]). These small, non-coding RNAs of approximately 20 nucleotides are potent gene expression regulators that have been found in a variety of body fluids, i.e., blood, saliva, and urine ([@B16]). Changes in miRNA expression have been implicated in common human disorders such as cardiovascular, autoimmune and neurodegenerative diseases, or in inflammatory states. Subsequently, several studies have been performed to characterize the expression of various miRNAs both intracellularly and extracellularly, advocating the role of miRNAs as potential diagnostic and prognostic markers ([@B4]). miRNAs act as "fine-tuners" of the immune system, regulating both pro- and anti-inflammatory actions ([@B14]). Their expression in stimulated immune or bystander cells can be altered, affecting inflammatory processes ([@B38]). In addition, intracellular miRNAs have been implicated as powerful endogenous factors in regulating inflammatory signaling cascades. Alternatively, as a part of the inflammatory response, the immune system is able to regulate the endogenous biogenesis of miRNAs at multiple levels ([@B9]). Previously, "inflammatory" miRNA altered expression has been shown in retinal tissue and blood plasma ([@B8]; [@B59]) as well as in peripheral blood mononuclear cells from AMD patients ([@B44]).

In the present study, we aimed to explore the expression of systemic inflammatory factors and selected intracellular miRNAs that regulate various inflammatory signaling pathways and processes potentially involved in AMD pathogenesis. We also focused on possible correlations of their expression with disease severity.

Materials and Methods {#S2}
=====================

Characteristics of the Study Group {#S2.SS1}
----------------------------------

Three hundred fifty-four patients with newly diagnosed AMD recruited from the outpatient population of the First Department of Ophthalmology of Pomeranian Medical University in Szczecin, Poland, were included in the study. The control group consisted of 121 age-matched participants with no symptoms or signs of macular degeneration (defined as the absence of drusen, pigmentary abnormalities or neovascularization). All of the enrolled subjects underwent a complete ophthalmic examination, i.e., visual acuity and intraocular pressure measurements, optical coherence tomography (OCT) analysis (Spectralis, Heidelberg Engineering, Heidelberg, Germany) and dilated fundus examination using slit-lamp biomicroscopy. Visual acuity (VA) was measured using a Snellen letter chart and transformed to LogMAR (Logarithm of the minimum angle of resolution) for statistical analyses.

In the group of recruited AMD patients, 179 subjects had a clinical diagnosis of wet AMD, with newly diagnosed choroidal neovascularization (CNV) characterized by serous or hemorrhagic retinal pigment epithelium detachment, subretinal neovascular membrane, subretinal hemorrhage, or fibrous scar. The rest of the examined AMD patients, i.e., one hundred seventy-five subjects, had a clinical diagnosis of dry AMD, with visible alterations in RPE in the form of geographic retinal atrophy and macular drusen. In the case of different stages of the disease being diagnosed in each eye, the subject was categorized according to the severity of changes in the worse eye. Exclusion criteria included significant chronic systemic conditions, for example, collagen or neoplastic disease, diabetes mellitus, renal failure, hepatic dysfunction or any evidence of retinal disease except AMD (in AMD groups), i.e., glaucoma or intraocular inflammatory diseases.

Data regarding medical history, current drug use, working conditions and smoking status were collected based on laboratory data, pathology tests, and other information, with a particular focus on heart and vascular conditions and pre-existing arterial hypertension. Furthermore, the actual arterial BP was directly measured prior to ophthalmic examination in all subjects using a non-invasive BP system with a manual aneroid manometer. The mean result from three measurements obtained with 5-min resting intervals was calculated. From the obtained BP data, the systemic mean arterial pressure (MAP) was calculated as follows: MAP = diastolic BP + 1/3 (systolic BP − diastolic BP) mmHg. Furthermore, the following medical parameters were assessed in all patients: waist circumference \[cm\], waist/hip ratio (WHR), and body mass index (BMI) \[weight (kg)/height (m)^2^\]. Cumulative pack-years were calculated using the reported average number of cigarettes smoked per day and the number of years of smoking.

The study adhered to the tenets of the Declaration of Helsinki, and approval was obtained from the Local Research Ethics Committee. Moreover, each patient provided written informed consent for his or her involvement.

Blood Sample Collection {#S2.SS2}
-----------------------

Venous blood samples (∼7.5 ml) collected in EDTA tubes were centrifuged (2000 rpm, 4°C, 10 min), and the plasma was stored at −20 to −80°C until assayed. The red blood cells were lysed using BD Pharm Lyse lysing buffer (BD Biosciences, San Jose, CA, United States) for 15 min at room temperature to isolate peripheral blood nuclear cells (PBNCs).

Luminex Assay {#S2.SS3}
-------------

TNF-α, IL-2, IL-1b, IL-4, IL-5, IL-6 IL-8, IL-10, IL-12 p70, GM-CSF, and IFN-γ concentrations were measured in plasma by multiplex fluorescent bead-based immunoassays (Luminex Corporation, Austin, TX, United States) using commercial R&D Systems Luminex Performance Human High Sensitivity Cytokine Magnetic Panel A (R&D Systems, Minneapolis, MN, United States). A total of 100 μL of blanks, standards and samples were added to the plate together with a Microparticle Cocktail and incubated in the dark for 3 h at room temperature on a horizontal orbital microplate shaker set at 800 rpm. After this step, the wells were washed with 100 μL of wash buffer three times by using a hand-held magnet. Biotin-antibody cocktail (50 μL) was added to the plate and incubated with agitation at room temperature for 60 min in the dark. After washing, 50 μL of streptavidin--PE was added to each well and incubated in the dark for 30 min on a plate shaker. Finally, after washing, the microspheres in each well were resuspended in 100 μL wash buffer and shaken for 2 min at room temperature. The plate was read and analyzed on the Luminex 200 analyzer, and cytokine concentrations were determined from seven different standard curves showing median fluorescence intensity vs. protein concentration.

miRNA Analysis {#S2.SS4}
--------------

We chose 13 miRNAs involved in inflammatory signaling pathways and processes potentially contributing to AMD to be tested in this study (miRNA-16-5p, miRNA-17-3p, miRNA-17-5p, miRNA-21-3p, miRNA-23a-3p, miRNA-30b, miRNA-126-3p, miRNA-126-5p, miRNA-146a, miRNA-150-5p, miRNA-155-5p, miRNA-191-5p, miRNA-223-3p) ([@B14]; [@B34]; [@B8]). miRNA for molecular analysis was obtained from PBNCs. Cellular RNA was isolated from 3 × 10^6^ nucleated cells using the mirVana Isolation Kit with organic phenol extraction (Thermo Fisher Scientific, Waltham, MA, United States) according to the manufacturer's protocol. RNA concentration was measured using an Epoch Microplate Spectrophotometer (BioTek, Winooski, VT, United States), and 100 ng was used for first strand cDNA synthesis. For cDNA synthesis, 4 μL of each sample was used. First strand cDNA synthesis was performed in all samples using a qScript microRNA cDNA Synthesis Kit (Quantabio, Beverly, MA, United States). qPCR for the assessment of miRNA expression was performed with Bio-Rad CFX96 Real-Time Detection System (Bio-Rad, CA, United States). The reaction solution consisted of 1 μL of cDNA sample, iQ SYBR Green Supermix (Bio-Rad, CA, United States), Universal Primer provided in qScript microRNA Synthesis Kit and a forward primer specific to miRNA analysis. Quantification of the target miRNA expression value was expressed as 2^ΔCt^. To find the best reference gene, the NormFinder algorithm was used ([@B3]); miR-93 was set as a reference miRNA.

Statistical Analysis {#S2.SS5}
--------------------

Quantitative parameters measured in both eyes were averaged before further analysis. Since the distribution of the quantitative variables was significantly different from the normal distribution in most cases, the non-parametric Kruskal--Wallis test followed by Siegel and Castellan's test was used to compare values between groups, and Spearman's rank correlation coefficient (Rs) was used to measure the strength of associations between them. Fisher's exact test was used to compare qualitative variables between groups. Multivariate analysis of AMD as an independent variable associated with concentrations of inflammatory factors and miRNAs or cell counts was performed using a general linear model (GLM) adjusted for age, sex and smoking status (pack-years), with logarithmic transformation applied to the dependent variables to normalize their distributions. Standardized regression coefficient (β) was used to measure strength of associations between independent and dependent variables. The sign of the Rs or β values (calculated for uni- and multivariate analysis, respectively) indicates the direction of the association (positive or negative), while higher absolute value (closer to −1 or +1) indicates stronger association. *P* \< 0.05 was considered statistically significant. Statistica 13 software (Dell Inc., OK, United States) was used for statistical analysis.

Results {#S3}
=======

Characteristics of the Study Subjects {#S3.SS1}
-------------------------------------

We enrolled 354 patients with AMD and 121 healthy controls in the study. A total of 175 patients presented with dry AMD and 179 with wet AMD. The clinical characteristics of the patients and controls are summarized in [Table 1](#T1){ref-type="table"}. Since epidemiological data collected so far indicate unquestionably that AMD is associated with the atherosclerosis we analyzed vascular-related risk factors in the study groups. The AMD and control groups were not significantly different as regards age and well-known atherosclerotic risk factors, including hypertension, history of ischemic heart disease, cardiac infarction, cerebral stroke, peripheral artery disease, and aortic aneurysm. The rate of past smokers and the number of smoking pack-years were significantly higher in wet than in dry AMD patients; these values were also higher in wet AMD patients than in controls. There were no significant differences in the BMI, MAP, iris color values or work conditions between the groups.

###### 

Characteristics of the study groups.

  **Parameter**                                    **Dry AMD group**   **Wet AMD group**   **Control group**   ***p*-value^∗^**                 
  ------------------------------------------------ ------------------- ------------------- ------------------- ------------------ ------------- -----------
  Number of subjects                               175                 179                 121                 --                 --            --
  Sex (male/female)                                52/123              83/96               32/89               0.60               **\>0.001**   **0.001**
  Patient's age \[years\] (mean ± SD)              72.7 ± 8.0          74.14 ± 7.92        73.1 ± 6.0          1.00               0.33          0.16
  BMI \[kg/m^2^\] (mean ± SD)                      26.94 ± 4.29        26.93 ± 4.17        26.56 ± 3.66        1.00               1.00          1.00
  WHR \[arbitrary units\] (mean ± SD)              0.88 ± 0.09         0.91 ± 0.09         0.88 ± 0.09         1.00               **0.02**      **0.006**
  Waist circumference \[cm\] (mean ± SD)           91.52 ± 12.53       94.24 ± 12.65       90.13 ± 11.62       1.00               **0.04**      0.18
  MAP \[mmHg\] (mean ± SD)                         97.10 ± 10.40       99.50 ± 11.65       98.72 ± 9.66        1.00               1.00          0.29
  Current smokers (%)                              10.63%              16.56%              6.25%               0.27               **0.02**      0.14
  Former smokers (%)                               45.00%              57.67%              30.93%              **0**.**03**       **\>0.001**   **0.03**
  Smoking pack-years (mean ± SD)\^                 10.06 ± 16.08       17.04 ± 20.80       6.00 ± 13.09        0.12               **\>0.001**   **0.01**
  Period without smoking \[years\] (mean ± SD)     6.31 ± 10.78        7.26 ± 11.03        5.30 ± 10.23        0.92               **\>0.001**   0.06
  Iris color (dark/light)                          45/129              46/132              26/95               0.41               0.41          1.00
  Outdoor/indoor working conditions                38.29/61.71%        41.90/58.10%        33.06/66.94%        0.39               0.15          0.52
  Hypertension (%)                                 65.00%              64.42%              71.13%              0.34               0.28          1.00
  Duration of hypertension \[years\] (mean ± SD)   8.44 ± 9.56         7.92 ± 9.36         9.15 ± 9.86         0.45               0.22          0.64
  History of ischemic heart disease (%)            15.09%              17.18%              11.34%              0.46               0.22          0.65
  Duration of ischemic heart disease \[years\]     1.35 ± 4.75         1.11 ± 3.52         0.81 ± 3.28         0.42               0.21          0.59
  (mean ± SD)                                                                                                                                   
  History of cardiac infarction (%)                7.55%               4.91%               6.19%               0.80               0.78          0.36
  History of cerebral stroke (%)                   3.18%               2.45%               3.09%               1.00               0.71          0.75
  History of peripheral artery disease (%)         3.77%               6.13%               6.19%               0.38               1.00          0.44
  History of aortic aneurysm (%)                   1.89%               1.25%               0.00%               0.29               0.53          0.68
  Hypotensive drugs/vasodilators                   65.00%              65.03%              70.10%              0.42               0.42          1.00
  Hormonal drugs                                   20.00%              14.29%              20.62%              1.00               0.23          0.19
  Thyroxine                                        15.63%              11.80%              20.62%              0.31               0.07          0.33
  Steroids                                         2.50%               1.24%               1.03%               0.65               1.00          0.45
  Other hormonal drugs                             1.25%               1.24%               0.00%               0.53               0.53          1.00
  Statins                                          26.88%              26.38%              36.08%              0.13               0.12          1.00
  NSAIDs                                           17.50%              22.84%              19.59%              0.74               0.64          0.27
  Cardiac medications/antiarrhythmic drugs         15.63%              12.27%              14.43%              0.86               0.70          0.42
  Antiasthmatic drugs                              5.63%               9.20%               3.09%               0.54               0.08          0.29
  Antidepressants                                  5.00%               4.32%               5.15%               1.00               0.77          0.80

In bold,

p

-value \< 0.05, which was considered statistically significant.

∗

Siegel and Castellan's test/Fisher's exact test; \^

p

\< 0.05 for comparison between 3 groups, Kruskal--Wallis test; BMI, body mass index; WHR, waist-hip ratio; MAP, mean arterial pressure; NSAIDs, non-steroidal anti-inflammatory drugs.

Blood Count Analysis {#S3.SS2}
--------------------

First, we performed a complete blood count analysis in all enrolled subjects ([Table 2](#T2){ref-type="table"}). We found that the WBC count values and proportion of neutrophils were significantly higher, in the wet AMD group compared with the values in the control group, while the proportion of lymphocytes appeared to be lower in the wet AMD group compared with the values in the control group. Wet AMD appeared to be associated with a higher WBC (β = +0.19, *p* = 0.004), a higher proportion of neutrophils (β = +0.199, *p* = 0.003) and a lower proportion of lymphocytes (β = −0.17, *p* = 0.009) in the multivariate analysis performed using a GLM after adjustment for age, sex and smoking status of the patient (pack-years). There were no differences in blood count analysis between dry AMD and control group, however, multivariate analysis performed using a GLM after adjustment for age, sex and smoking status of the patient (pack-years) revealed that dry AMD was an independent factor associated with a higher proportion of neutrophils (β = +0.13, *p* = 0.05) and a lower proportion of lymphocytes (β = −0.14, *p* = 0.02).

###### 

Complete blood count results in the study groups.

  **Parameter**                  **Dry AMD group**   **Wet AMD group**   **Control group**   **p-value^∗^**                 
  ------------------------------ ------------------- ------------------- ------------------- ---------------- ------------- -----------
  WBC Count \[^∗^10^3^/μl\]^∧^   6.35 ± 1.83         6.89 ± 1.92         6.12 ± 1.71         0.91             **0.001**     **0.01**
  Lymphocytes (%)^∧^             31.70 ± 8.33        30.64 ± 7.84        33.33 ± 8.79        0.35             **0.02**      0.58
  Monocytes (%)                  8.93 ± 1.98         8.67 ± 2.26         8.67 ± 1.78         1.00             1.00          0.48
  Neutrophils (%)^∧^             55.98 ± 8.96        57.54 ± 9.08        54.70 ± 9.26        0.81             **0.02**      0.19
  Eosinophils (%)                2.68 ± 1.70         2.51 ± 1.96         2.64 ± 2.28         1.00             1.00          0.22
  Basophils (%)                  0.71 ± 0.33         0.59 ± 0.36         0.66 ± 0.35         0.59             1.00          0.19
  RBC Count \[^∗^10^6^/μl\]      4.62 ± 0.45         4.70 ± 0.38         4.62 ± 0.36         1.00             0.13          0.11
  Hemoglobin \[g/dl\]            8.61 ± 0.82         8.75 ± 0.75         8.64 ± 0.62         1.00             0.34          0.18
  Hematocrit \[^∗^100%\]^∧^      0.41 ± 0.04         0.42 ± 0.03         0.41 ± 0.03         1.00             **0.04**      0.07
  MCV \[fl\]                     89.00 ± 4.32        88.91 ± 4.35        88.64 ± 3.49        0.56             0.92          1.00
  MCH \[pg\]                     1.87 ± 0.11         1.86 ± 0.11         1.87 ± 0.08         1.00             1.00          1.00
  MCHC \[g/dl\]                  21.00 ± 0.63        20.97 ± 0.61        21.16 ± 0.57        0.19             0.07          1.00
  RDW \[%\]^∧^                   13.28 ± 1.17        13.53 ± 1.09        13.12 ± 0.91        0.94             **\>0.001**   **0.008**
  Platelets \[^∗^10^3^/μl\]      231.14 ± 61.17      225.03 ± 53.46      227.56 ± 59.77      1.00             1.00          1.00
  MPV \[fl\]                     10.49 ± 0.93        10.47 ± 0.87        10.43 ± 0.83        1.00             1.00          1.00

In bold,

p

-values \< 0.05, which were considered statistically significant.

∗

Siegel and Castellan's test;

∧

p

\< 0.05 for comparison between 3 groups, Kruskal--Wallis test; WBC, white blood cells; RBC, red blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell distribution width; MPV, mean platelet volume.

Inflammatory Factor Levels {#S3.SS3}
--------------------------

To assess the systemic inflammatory response, we chose 11 factors for analysis in plasma: TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, GM-CSF, and IFN-γ. The wet AMD group presented with higher levels of 3 (IL-6, GM-CSF, IFN-γ) and lower concentrations of 4 (IL-1β, IL-5, IL-10, IL-12) tested cytokines in comparison with the control group ([Table 3](#T3){ref-type="table"}). Multivariate analysis of patients and controls, adjusted for age, sex and smoking status (pack-years), revealed that wet AMD was an independent factor associated with higher concentrations of IL-6 (β = +0.24, *p* = 0.0004), GM-CSF (β = +0.31, *p* \< 0.001) and IFN-γ (β = +0.58, *p* \< 0.001) and lower concentration of IL-1β (β =−0.25, *p* = 0.0003), IL-5 (β = −0.45, *p* \< 0.001), IL-10 (β = −0.45, *p* \< 0.001) and IL-12 (β = −0.35, *p* \< 0.001). Accordingly, dry AMD group presented with lower concentrations of 5 analyzed factors (IL-1β, IL-2, IL-5, IL-10, IL-12) and only one cytokine -- GM-CSF concentration being higher as compared with controls. Multivariate analysis of patients and controls, adjusted for age, sex and smoking status (pack-years), revealed that dry AMD was an independent factor associated with lower concentrations of TNF-α (β = +0.24, *p* = 0.0004), IL-1β (β = −0.39, *p* \< 0.001), IL-2 (β = −0.20, *p* = 0.003), IL-5 (β = −0.54, *p* \< 0.001), IL-10 (β = −0.56, *p* \< 0.001), IL-12 (β = −0.51, *p* \< 0.001) and higher concentration of GM-CSF (β = +0.34, *p* \< 0.001) and IL-6 (β = +0.13, *p* = 0.05). AMD subtype analysis revealed statistically significant differences in the concentrations of 7 tested factors (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-γ), all of which were elevated in the wet AMD group compared to the concentrations in the dry AMD group ([Table 3](#T3){ref-type="table"}). Interestingly, in AMD patients, we observed negative correlations between the percentage of lymphocytes and TNF-α (Rs = −0.14; *p* = 0.02), IL-2 (Rs = −0.14; *p* = 0.02), IL-5 (Rs = −0.17; *p* = 0.004), IL-6 (Rs = −0.19; *p* = 0.002), IL-10 (Rs = −0.18; *p* = 0.003), and IL-12 (Rs = −0.20; *p* = 0.001) and positive correlations between the percentage of neutrophils and TNF-α (Rs = +0.14; *p* = 0.02), IL-1β (Rs = +0.13; *p* = 0.03), IL-2 (Rs = + 0.15; *p* = 0.02), IL-5 (Rs = +0.16; *p* = 0.009), IL-6 (Rs = +0.18; *p* = 0.003), IL-10 (Rs = +0.18; *p* = 0.003), and IL-12 p70 (Rs = +0.21; *p* = 0.0008). Such correlations were not observed in the controls.

###### 

Comparison of inflammatory factor levels in dry and wet AMD patients in comparison with control group.

                           **Dry AMD group**   **Wet AMD group**   **Control group**   ***p*-value^∗^**                                                     
  ------------------------ ------------------- ------------------- ------------------- ------------------ ----- --------------- ------------- ------------- -------------
  TNF-α \[pg/mL\]          138                 3.630 ± 2.019       135                 3.908 ± 2.001      116   4.008 ± 1.702   0.09          1.00          0.59
  IL-1β \[pg/mL\]^∧^       138                 0.490 ± 0.264       135                 0.571 ± 0.473      116   0.770 ± 0.572   **\>0.001**   **\>0.001**   0.27
  IL-2 \[pg/mL\]^∧^        138                 0.260 ± 0.551       135                 0.415 ± 0.644      116   0.296 ± 0.325   **0.002**     1.00          **0.004**
  IL-4 \[pg/mL\]^∧^        138                 7.060 ± 7.197       135                 10.613 ± 10.025    116   7.354 ± 5.810   0.60          0.33          **0.008**
  IL-5 \[pg/mL\]^∧^        138                 0.329 ± 0.289       135                 0.438 ± 0.320      116   0.779 ± 0.531   **\>0.001**   **\>0.001**   **\>0.001**
  IL-6 \[pg/mL\]^∧^        138                 2.899 ± 4.544       135                 7.383 ± 31.517     116   1.802 ± 1.433   1.00          **0.02**      **0.04**
  IL-8 \[pg/mL\]           138                 4.701 ± 2.464       135                 4.881 ± 2.946      116   4.427 ± 2.080   1.00          1.00          1.00
  IL-10 \[pg/mL\]^∧^       138                 0.737 ± 0.551       135                 0.987 ± 1.224      116   1.696 ± 1.112   **\>0.001**   **\>0.001**   **0.009**
  IL-12 p70 \[pg/mL\]^∧^   138                 0.709 ± 1.257       134                 1.112 ± 1.445      116   1.882 ± 1.448   **\>0.001**   **\>0.001**   **0.02**
  GM-CSF \[pg/mL\]^∧^      138                 0.427 ± 0.391       132                 0.419 ± 0.516      116   0.271 ± 0.286   **\>0.001**   **\>0.001**   1.00
  IFN-γ \[pg/mL\]^∧^       67                  1.216 ± 0.656       70                  2.496 ± 2.978      43    1.073 ± 1.616   1.00          **\>0.001**   **\>0.001**

In bold,

p

-value \< 0.05, which was considered statistically significant. N, number of observations;

∗

Siegel and Castellan's test;

∧

p

\< 0.05 for comparison between 3 groups, Kruskal--Wallis test; TNF-α, tumor necrosis factor; IL-1β, interleukin-1β; IL-2, interleukin-2; IL-4, interleukin-4; IL-5, interleukin-5; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IL-12 p70, interleukin-12p70; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ.

Subsequently, we assessed the effect of the severity of underlying disease on the systemic inflammatory response and investigated the association between the concentrations of analyzed cytokines and cell counts and selected clinical parameters. Remarkably, we found negative correlations between visual acuity and selected analyzed inflammatory factors (Rs = −0.155, *p* = 0.01 for TNF-α; Rs = −0.13, *p* = 0.03 for IL-1β, Rs = −0.141, *p* = 0.02 for IL-2, Rs = −0.164, *p* = 0.006 for IL-4, Rs = −0.209, *p* = 0.0005 for IL-6, Rs = −0.147, *p* = 0.02 for IL-10), as well as negative correlations between visual acuity and WBC (Rs = −0.176, *p* = 0.0016) and lymphocyte count (Rs = −0.117, *p* = 0.036). Notably, no such correlations were found in the control group. Likewise, we observed significant associations between analyzed factors and retinal and choroidal parameters. We found negative correlations between central choroidal thickness values and selected analyzed inflammatory factors (Rs = −0.171, *p* = 0.005 for IL-5, Rs = −0.150, *p* = 0.01 for IL-10), as well as positive correlations between central retinal thickness values and WBC (Rs = +0.125, *p* = 0.023) and selected analyzed inflammatory factors (Rs = +0.163, *p* = 0.007 for IL-2, Rs = +0.143, *p* = 0.02 for IL-4, Rs = +0.292, *p* = 0.0005 for IFN-γ). Notably, no such correlations were observed in the control group. This indicates that patients with a more advanced stage of disease display higher plasma levels of inflammatory cytokines.

Cellular miRNA Expression Profiles {#S3.SS4}
----------------------------------

Next, we performed a quantitative analysis of the expression of the selected miRNAs in peripheral blood cells (PBNCs) of AMD and control patients using qRT-PCR. We chose a panel of 13 miRNAs (miRNA-16-5p, -17-3p, -17-5p, -21-3p, -23a-3p, -30b, -126-3p, -126-5p, -146a, -150-5p, -155-5p, -191-5p, and -223-3p). Of the 13 analyzed miRNAs, four (miRNA-23a-3p, miRNA-30b, miRNA-191-5p, and miRNA-223-3p) showed higher expression, whereas four (miRNA-16-5p, miRNA-17-3p, miRNA-150-5p, and miRNA-155-5p) showed lower expression in the PBNCs of wet AMD patients compared with the expression in the PBNCs of control patients ([Table 4](#T4){ref-type="table"}). Multivariate analysis of patients and controls, adjusted for age, sex and smoking status (pack-years), revealed that wet AMD was an independent factor associated with higher expression of miRNA-23a-3p (β = +0.60, *p* \< 0.0001), miRNA-30b (β = +0.32, *p* \< 0.0001), miRNA-191-5p (β = +0.28, *p* \< 0.0001) and lower expression of miRNA-16-5p (β = −0.31, *p* \< 0.0001), miRNA-17-3p (β = −0.18, *p* = 0.01), miRNA-150-5p (β = −0.18, *p* = 0.01) and miRNA-155-5p (β = −0.47, *p* \< 0.0001). Accordingly, dry AMD group presented with higher expression of four (miRNA-23a-3p, miRNA-126-3p, miRNA-126-5p, and miRNA 146a) and lower expression of three (miRNA-16-5p, miRNA-17-3p, and miRNA-17-5p) miRNAs in the PBNCs as compared with controls. Multivariate analysis of patients and controls, adjusted for age, sex and smoking status (pack-years), revealed that dry AMD was an independent factor associated with higher expression of miRNA-23a-3p (β = +0.60, *p* \< 0.0001), miRNA-126-3p (β = +0.23, p = 0.0005), miRNA-126-5p (β = +0.16, *p* = 0.01) and miRNA 146a (β = +0.14, *p* = 0.03), mRNA191-5p (β = +0.15, *p* = 0.03) and lower expression of miRNA-16-5p (β = −0.23, *p* = 0.0004), miRNA-17-3p (β = −0.20, *p* = 0.003) and miRNA-17-5p (β = −0.19, *p* = 0.004). Cellular miRNA profiles were distinct between wet and dry AMD patients ([Table 4](#T4){ref-type="table"}). Of six differentially expressed miRNAs in AMD subtypes, four (miRNA-126-3p, miRNA-126-5p, miRNA-150-5p, and miRNA-155-5p) were upregulated in the PBNCs of dry AMD patients, whereas two (miRNA-30b and miRNA-191-5p) showed higher expression in the PBNCs of wet AMD patients.

###### 

Cellular miRNA profiles in dry and wet AMD patients in comparison with control group.

                    **Dry AMD group**   **Wet AMD group**   **Control group**   ***p*-value^∗^**                                                     
  ----------------- ------------------- ------------------- ------------------- ------------------ ----- --------------- ------------- ------------- -------------
  miRNA-16-5p^∧^    153                 0.726 ± 0.306       145                 0.695 ± 0.175      112   0.802 ± 0.209   **\>0.001**   **\>0.001**   1.00
  miRNA-17-3p^∧^    154                 0.405 ± 0.604       144                 0.481 ± 0.786      113   0.561 ± 0.838   **0.01**      **0.02**      1.00
  miRNA-17-5p^∧^    154                 0.942 ± 0.333       144                 0.975 ± 0.786      112   1.056 ± 0.298   **0.003**     0.12          0.59
  miRNA-21-3p       154                 1.396 ± 0.995       145                 1.188 ± 0.787      113   1.423 ± 2.626   0.55          1.00          0.29
  miRNA-23a-3p^∧^   154                 1.328 ± 0.573       145                 1.257 ± 0.422      113   0.541 ± 0.517   **\>0.001**   **\>0.001**   1.00
  miRNA-30b^∧^      154                 0.810 ± 0.264       145                 0.930 ± 0.328      112   0.749 ± 0.267   0.21          **\>0.001**   **0.001**
  miRNA-126-3p^∧^   154                 0.449 ± 0.418       144                 0.296 ± 0.255      113   0.280 ± 0.217   **0.002**     1.00          **\>0.001**
  miRNA-126-5p^∧^   154                 0.302 ± 0.330       144                 0.213 ± 0.230      112   0.220 ± 0.253   **0.02**      1.00          **0.006**
  miRNA-146a^∧^     154                 0.883 ± 0.477       145                 0.795 ± 0.422      113   0.764 ± 0.253   **0.03**      0.83          0.32
  miRNA-150-5p^∧^   154                 1.605 ± 1.345       145                 1.186 ± 1.066      113   1.400 ± 0.980   1.00          **0.04**      **\>0.001**
  miRNA-155-5p^∧^   154                 0.507 ± 0.794       145                 0.176 ± 0.537      112   0.542 ± 0.716   0.27          **\>0.001**   **\>0.001**
  miRNA-191-5p^∧^   154                 2.240 ± 1.286       145                 2.509 ± 1.132      113   2.037 ± 1.165   0.78          **\>0.001**   **0.02**
  miRNA-223-3p      154                 0.838 ± 0.420       145                 0.842 ± 0.253      112   0.797 ± 0.350   0.80          **0.04**      0.11

In bold,

p

-value \< 0.05, which was considered statistically significant. N, number of observations;

∗

Siegel and Castellan's test;

∧

p

\< 0.05 for comparison between 3 groups, Kruskal--Wallis test; Expression is calculated in relation to miR-93 as reference miRNA.

Subsequently, we assessed the effect of the severity of underlying disease on the miRNA profile and investigated the association between the expression of analyzed molecules and selected clinical parameters. Remarkably, we observed positive correlations between visual acuity and selected miRNA expression (Rs = +0.243, *p* = 0.00002 for miRNA-126-3p; Rs = +0.199, *p* = 0.0005 for miRNA-126-5p; Rs = +0.144, *p* = 0.01 for miRNA-155-5p), as well as negative correlations between visual acuity and miRNA-191-5p (Rs = −0.153, *p* = 0.008). Notably, no such correlations were found in the control group. Likewise, we observed significant associations between the analyzed miRNA profile and retinal and choroidal parameters. We found a positive correlation between central choroidal thickness values and miRNA 126-3p expression (Rs = +0.149, *p* = 0.01), as well as significant correlations between the thickness of the central retina and the expression of miRNA-126-3p (Rs = -0.119, p = 0.04), miRNA-155-5p (Rs = −0.177, *p* = 0.002) and miRNA-191-5p (Rs = +0.175, *p* = 0.002). Notably, no such correlations were found in the control group.

miRNA Correlations {#S3.SS5}
------------------

To more accurately characterize the role of the analyzed miRNA profiles in AMD patients, we evaluated the association between the expression of miRNA molecules and inflammatory factor plasma level analysis. We aimed to investigate whether certain miRNAs are linked with inflammatory factors and whether these correlations are specific for AMD patients or wet/dry AMD subtypes. In general, we found that the expression of analyzed miRNA molecules strongly correlated with the levels of tested inflammatory factors in AMD patients, whereas such correlations were not observed in controls ([Table 5](#T5){ref-type="table"}). The miRNA with the highest expression from the tested panel in both dry and wet AMD groups, miRNA-191-5p, was significantly correlated with almost all inflammatory factor concentrations \[TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12 (p70), and GM-CSF\] in these subjects, while no such correlations were found in controls. Strong positive correlations between the expression of miRNA-191-5p and IL-2 and IL-6 levels in the wet AMD group corresponded to significant upregulation of both miRNA-191-5p, IL-2 and IL-6 in these patients. Similar positive correlations between this miRNA and these factors were also observed in dry AMD group, but not in controls. Negative correlations between two factors strongly elevated in wet AMD patients (IL-4, IL-6) and miRNA-30b and miRNA-146a were exclusive for this group and not observed in dry AMD or control group. In fact, these two miRNAs (miRNA-30b, miRNA-146a) showed only negative correlations (which were statistically significant) with most of the analyzed inflammatory factors in both dry and wet AMD groups. The observed diversity of miRNA-inflammatory factor correlations reflects the vast variety of biological processes that these miRNAs regulate.

###### 

Spearman's correlation coefficients for cellular miRNAs and inflammatory factors in dry and wet AMD patients in comparison with control group.

  ------------------------------
  ![](fnagi-11-00286-t005.jpg)
  ------------------------------

Statistically significant results (p \< 0.05) are shown in bold. The gray background corresponds to unique correlations, which were statistically significant only in AMD patients, not controls.

Discussion {#S4}
==========

AMD is a complex disease of the central retina and is a major cause of blindness in developed countries, significantly affecting the quality of life of millions. However, the pathogenesis of AMD is not currently completely understood. The involvement of various processes (e.g., oxidative stress, pathological angiogenesis, inflammation, and lipid oxidation) in AMD has been proposed, and it seems that both environmental and genetic factors are equally important in disease pathology. In this study, we focused on two potentially major contributors to AMD pathogenesis: inflammation and miRNAs. First, we aimed to address whether pathological processes in AMD, basically limited to the retina, could also be reflected in systemic changes in inflammatory factors and cellular miRNA expression profiles. We also attempted to correlate these results with selected clinical characteristics (e.g., visual acuity or central retinal/choroidal thickness) in AMD patients.

First, we performed an initial assessment of systemic markers of inflammation in AMD patients with a complete white blood cell count. The significantly increased WBC and neutrophil count and low lymphocyte number in wet AMD observed in this study are in concordance with previous research. In a large study of over 3,000 AMD patients, an elevated WBC count was linked with early AMD incidence, independent of smoking and other major confounders ([@B69]). Recently, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been proposed as indicators of systemic inflammation; both ratios have been shown to be increased in AMD patients ([@B54]). According to [@B67], chronic inflammation leads to increased neutrophil and monocyte counts and decreased lymphocyte counts due to augmentation of apoptosis. Although [@B58] recently suggested that blood count-derived inflammation biomarkers are unreliable in AMD, their study was performed in a small group of 79 male patients. The difference in NLR and PLR between dry and wet AMD subtypes also draws interest ([@B26]).

Next, we tested selected inflammatory factor concentrations in blood samples and found that many of them were dysregulated in AMD patients, specifically in the wet AMD subtype. In our study, the inflammatory factor profile in wet AMD patients was similar to that of previously published studies, especially with notable IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IFN-γ increases ([@B66]; [@B30]). It was found that paracrine factors released from reactive retinal microglia can trigger NLRP3 inflammasome activation in the RPE cells, which in response augment expression of pro-inflammatory marker genes, such as IL-1ß, IL-6, IL-8, and GM-CSF in these cells ([@B53]). The increased expression of pro-inflammatory cytokines including IL-1β and IL-6 in inflammasome-triggered RPE cells may indicate the more stressed RPE cells and highly negative effects on AMD progression *in vivo*. In this notion, in our study we found that wet AMD was associated with higher concentrations of several pro-inflammatory cytokines, such as IL-6, GM-CSF, and IFN-γ, whereas dry form of the condition is accompanying with higher levels of GM-CSF and IL-6. GM-CSF is generally recognized as an pro-inflammatory cytokine and its inflammatory activity is primarily due its role as a growth and differentiation factor for myeloid lineage cells including granulocyte and macrophage populations. Mostly, the pro-inflammatory effects of GM-CSF appear to depend on the dose and the presence of other relevant cytokines in the context of an immune response ([@B68]). In the retina, GM-CSF promotes the survival and activation of microglia and perivascular macrophages ([@B22]). Importantly, Wang et al., found that GM-CSF is elevated in the vitreous humor of eyes having the at-risk homozygous CC variant in the complement factor H (CFH) gene ([@B73]). The polymorphism in this gene is a known genetic risk factor for AMD, where the CFH Y402H single nucleotide polymorphism is strongly associated with inflammation characterized by increased pro-inflammatory cytokines and oxidative stress-related molecules systemically in circulation and locally in the eye tissues ([@B73]). These data were also confirmed by the same group of [@B73] through the *in vitro* studies, where they observed that stimulation of RPE cells with complement activation products, C3a and C5a, promotes upregulation of GM-CSF expression in RPE culture. In addition, stimulation of cultured RPE cells with proinflammatory TNF-α cytokine promoted strong secretion of GM-CSF to the environment *in vitro*. Moreover, GM-CSF may promote retinal neovascularization by releasing VEGF from neutrophils attracted to the subretinal space ([@B56]). Besides, the correlations between AMD severity and WBC count and inflammatory factor levels observed in our study are worth noting. Negative correlations of pro-inflammatory cytokines with visual acuity shown in this study might bring us a step further in establishing the specific inflammation-related factor panel for potential use in diagnosis and monitoring of the progression of AMD.

To further explore the involvement of inflammation in AMD pathogenesis, we decided to study selected endogenous miRNA expression in peripheral blood circulating mononuclear cells, which are crucial components of complete immune system activity and thus may have important significance in modulating the inflammatory signaling pathways involved in the process of retinal degeneration in the course of AMD. Likewise, a recent report showed highly overexpressed endogenous miRNA-150 in circulating peripheral blood mononuclear cells from AMD patients, which could regulate macrophage-mediated inflammation and pathologic retinal angiogenesis independently from vascular endothelial growth factor (VEGF) ([@B44]). This finding was also correlated with an increased number of choroidal macrophages observed in human eyes with AMD, thus promoting pathological local neovascularization ([@B50]). These data strongly implicate a pathogenic role of different intracellular miRNAs expressed in immune-related cells circulating in peripheral blood in AMD patients. Moreover, given that different miRNAs can act in a cell-specific and unique manner, potential differences in modulation of the inflammatory status by distinct immune-related cells highlight their importance in AMD pathogenesis and its progression. In our study, the PBNCs miRNA with the highest overall expression was miRNA-191-5p, and according to our knowledge, it has not yet been described in AMD patients. Importantly, miRNA-191-5p is a potent player in neuronal development ([@B36]) and differentiated malignant cell biology ([@B51]), including retinoblastoma ([@B49]). In a recent study by [@B39] miRNA-191-5p was a part of the 7-miRNA signature, which could distinguish patients with Alzheimer's disease (AD) from normal controls with great accuracy (AUC of 0.953). Since both AD and AMD share similarities in their intra- and extracellular deposits ([@B31]), the role of miRNA-191-5p in AMD could be significant. Specifically, Lykken and Li described the importance of miRNA-191-5p in supporting cytokine-dependent naïve, memory, and regulatory T-cell survival for homeostasis by controlling the levels of insulin receptor substrate-1 (IRS1) and thereby the activation kinetics of intracellular signaling with STAT5 ([@B46]). IRS1 associates with JAK1 and JAK3 in the absence of cytokines; IL-2 or IL-4 addition increases this association ([@B29]). The positive correlation of miRNA-191-5p expression and IL-2 concentration in our study is in agreement with its biological function, similar to its correlation with IL-6, as IL-6 is an established target of miRNA-191-5p ([@B71]). Furthermore, the significant correlations of miRNA-191-5p expression with clinically important signs of retinal dysfunction, such as visual acuity (negative) and central retinal thickness (positive), might indicate a crucial role for this specific intracellular miRNA in AMD development and progression.

Another link between miRNA profiles in AD and AMD comes from a recent study on Aβ-injected rats and AMD patients, in which miR-9, miR-23, miR-2, miR-34, miR-146, and miR-155 were found to be dysregulated both in AMD and AD ([@B63]). A similar pattern of miRNA-23 and miRNA-146 upregulation and miRNA-155 downregulation, as we observed, in the aforementioned study was linked with several inflammatory signaling pathways (mTOR, TNFα, HIF signaling, and NF-κB) and insulin receptor signaling function, comparable to the mechanisms mentioned above for miRNA-191-5p. According to various studies, miRNA-155 exhibits both pro- and anti-inflammatory functions, depending on the stimulant involved ([@B62]; [@B70]). We found a negative correlation between miRNA-155 expression and inflammatory cytokine levels in AMD patients, which is in line with this miRNA pathway: it acts with IL-1 ([@B11]), TNF-α ([@B43]), NF-κB ([@B75]), MyD88 and the inositol 5′-phosphatase SHIP-1 in infected macrophages ([@B7]). In miRNA-155-deficient mice, TNF-α and IL-6 are markedly increased ([@B78]), while microglia and Treg lymphocyte cell numbers are reduced, possibly due to their impaired development ([@B37]; [@B77]). Furthermore, in a mouse model of oxygen-induced retinopathy, under ischemic conditions, downregulated miRNA-155 expression stimulated the increased inflammatory-related cytokine secretion and microglial activation, prompting aberrant angiogenic responses in the retina ([@B77]). Several other experiments performed *in vitro* and *in vivo* by other groups corroborated data obtained primarily in the miR-155 knock-out mice indicating that miR-155 may have a similar cell-type specific function in the microglia, endothelial cells, RPE cells and other cell types implicated in AMD pathogenesis ([@B8]). Thus, physiological miRNA-155 function appears to modulate inflammation-induced vascular injury and to induce its repair. In fact, we found miRNA-155 to be significantly downregulated in both examined forms of AMD compared to controls and to be even more substantially diminished in patients with the wet AMD type. In accordance with its inflammation-limiting role, the observed miRNA-155 positive correlation with visual acuity in our AMD group may further strongly highlight its role in linking inflammation and angiogenesis ([@B41]; [@B81]).

miRNA-126 and miRNA-146, known as potent angiogenesis- and inflammation-regulating miRNAs, provide another important link between these processes in the pathogenesis of AMD ([@B21]). In our study, their endogenous expression was elevated in circulating cells of AMD patients and was correlated negatively with soluble inflammatory factors; miRNA-126 expression was also increased in dry AMD patients and correlated with clinical ophthalmological parameters. Both possess mostly anti-inflammatory roles, regulating NF-κB transcriptional activity and the biosynthesis of IL-1β, IL-6, IL-8, IL-10 and TNF-α and alleviating chemotactic effects toward macrophages via inhibition of TRAF6 activity ([@B42]; [@B76]). miRNA-146 elevation has been widely studied in association with pro-inflammatory neurodegeneration in AD and AMD ([@B1]). The upregulation of intracellular expression of both miRNA-126 strands (miR-126-3p and -5p) in immune-related cells in patients with dry AMD, together with their significant correlations with ophthalmological parameters related to retinal function, might suggest a general systemic attempt to suppress inflammation in remote organs or tissues, possibly similar to miRNA-146 overexpression, but the dual role of miRNA-126-3p and -5p strands in AMD angiogenesis remains to be further elucidated ([@B80]).

Another two strands of intracellular miRNA that we studied were miRNA-17 (-3p, -5p), a component of the polycistronic miR-17-92 cluster, which is a negative regulator of angiogenesis. A previous study showed increased expression of extracellular miRNA-17 in the plasma of AMD patients ([@B17]) in contrast to our results observed intracellularly, although sample choice (plasma/cells) could have affected these discrepancies. MiRNA-17 is well known for its emerging role in inflammation ([@B40]), in line with our results highlighting its correlation with inflammatory factor levels in the plasma of recruited AMD patients.

Altogether, the observed associations of the expression of different endogenous miRNAs in immune-related cells circulating in peripheral blood and several examined systemic inflammatory factors as well as differences between their expression in AMD/controls and wet/dry AMD groups may suggest the role of both intra- and extracellular mechanisms implicated in inflammatory response regulation in multifactorial AMD pathogenesis.

A limitation of the study is that the results cover one clinical time-point in the course of AMD. Moreover, this is an observational study and further experimental studies could be valuable. Particularly, experiments *in vivo* using miRNA knock-out mice could be considered to assess unique and overlapping biological characteristics of analyzed miRNAs and to unveil their pathological functions in these alive models. Such experimental studies could create a basis for potential therapeutic manipulation. Thus, we believe that the results described here form a solid basis for designing future studies to explore complex pathogenesis of AMD.

Conclusion {#S5}
==========

In conclusion, we found significantly modified miRNA expression levels in peripheral blood cells (miRNA-16-5p, miRNA-17-3p, miRNA-17-5p, miRNA-23a-3p, miRNA-30b, miRNA-126-3p, miRNA-146a, miRNA-155-5p, and miRNA-191-5p) and soluble inflammatory factor concentrations in the plasma of AMD patients (IL-2, GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, and IL-12), suggesting that, among others, these biologically active molecules have an important role in AMD. Our results could provide another tool to further explore the complex pathogenesis of this neurodegenerative disease, affecting elderly people. However, it remains to be determined whether these differences are a result of inflammatory processes in the retina in the course of AMD or if they are a reflection of a systemic response aimed at reducing the AMD-derived retinal damage or perhaps both. Further interventional studies with inflammation-modulating compounds might clarify to what degree the influence of inflammation is causative or contributory in AMD pathogenesis.
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